ICD-10 Logo
ICDxICD-10 Medical Coding
ICD-10 Logo
ICDxICD-10 Medical Coding
ICD 10 CodesDiagnoses
ICD 10 CodesDiagnoses
ICD-10 Logo
ICDxICD-10 Medical Coding

Comprehensive ICD-10-CM code reference with AI-powered search capabilities.

© 2025 ICD Code Compass. All rights reserved.

Browse

  • All Chapters
  • All Categories
  • Diagnoses

Tools

  • AI Code Search
ICD-10-CM codes are maintained by the CDC and CMS. This tool is for reference purposes only.
v1.0.0
ICD-10 Guide
ICD-10 CodesR89

R89

Abnormal findings in specimens from other organs, systems and tissues

BILLABLE STATUSNo
IMPLEMENTATION DATEOctober 1, 2015
LAST UPDATED09/05/2025

Code Description

ICD-10 R89 is a used to indicate a diagnosis of abnormal findings in specimens from other organs, systems and tissues.

Key Diagnostic Point:

The ICD-10 Level 1 Category code R89 pertains to abnormal findings in specimens derived from various organs, systems, and tissues. This category encompasses a wide range of conditions that may not have a specific diagnosis but indicate the presence of an abnormality that requires further investigation. Such findings can arise from laboratory tests, biopsies, or other diagnostic procedures, and may include issues like abnormal cell counts, unusual tissue morphology, or unexpected biochemical markers. Clinically, these findings can guide healthcare providers in determining the need for additional diagnostic workup or monitoring, thereby playing a crucial role in patient management.

Code Complexity Analysis

Complexity Rating: Medium

Medium Complexity

Complexity Factors

  • Variety of conditions covered
  • Need for further diagnostic clarification
  • Potential for misinterpretation of findings

Audit Risk Factors

  • Inadequate documentation of findings
  • Misuse of the code for specific diagnoses
  • Failure to follow up on abnormal findings

Specialty Focus

Medical Specialties

Pathology

Documentation Requirements

Standard ICD-10-CM documentation requirements apply

Common Clinical Scenarios

Various clinical presentations within this specialty area

Billing Considerations

Follow specialty-specific billing guidelines

Laboratory Medicine

Documentation Requirements

Standard ICD-10-CM documentation requirements apply

Common Clinical Scenarios

Various clinical presentations within this specialty area

Billing Considerations

Follow specialty-specific billing guidelines

Related Codes

Child Codes

10 codes
R89.0
Abnormal level of enzymes in specimens from other organs, systems and tissues
R89.1
Abnormal level of hormones in specimens from other organs, systems and tissues
R89.2
Abnormal level of other drugs, medicaments and biological substances in specimens from other organs, systems and tissues
R89.3
Abnormal level of substances chiefly nonmedicinal as to source in specimens from other organs, systems and tissues
R89.4
Abnormal immunological findings in specimens from other organs, systems and tissues
R89.5
Abnormal microbiological findings in specimens from other organs, systems and tissues
R89.6
Abnormal cytological findings in specimens from other organs, systems and tissues
R89.7
Abnormal histological findings in specimens from other organs, systems and tissues
R89.8
Other abnormal findings in specimens from other organs, systems and tissues
R89.9
Unspecified abnormal finding in specimens from other organs, systems and tissues

Related CPT Codes

CPT Code

Clinical Scenario

Documentation Requirements

CPT Code

Clinical Scenario

Documentation Requirements

CPT Code

Clinical Scenario

Documentation Requirements

ICD-10 Impact

Diagnostic & Documentation Impact

Enhanced Specificity

ICD-10 Improvements

The clinical and administrative impact of the R89 code category is significant, as it highlights the importance of identifying and addressing abnormal findings in patient specimens. This category plays a vital role in quality measures and population health initiatives, as timely recognition of abnormalities can lead to early intervention and improved patient outcomes. Furthermore, as healthcare trends shift towards value-based care, the ability to accurately document and code for these findings becomes increasingly important in demonstrating the quality of care provided and in managing healthcare costs effectively.

ICD-9 vs ICD-10

The clinical and administrative impact of the R89 code category is significant, as it highlights the importance of identifying and addressing abnormal findings in patient specimens. This category plays a vital role in quality measures and population health initiatives, as timely recognition of abnormalities can lead to early intervention and improved patient outcomes. Furthermore, as healthcare trends shift towards value-based care, the ability to accurately document and code for these findings becomes increasingly important in demonstrating the quality of care provided and in managing healthcare costs effectively.

Reimbursement & Billing Impact

Reimbursement may vary based on the payer and the specific tests conducted, so it is crucial to verify coverage policies and requirements for laboratory services. Additionally, accurate coding is essential to avoid claim denials and ensure appropriate payment for the services rendered.

Resources

Clinical References

  • •
    Official ICD-10 Guidelines for R89

Coding & Billing References

  • •
    Official ICD-10 Guidelines for R89

Frequently Asked Questions

What conditions are included in R89?

R89 includes abnormal findings from laboratory tests, biopsies, and other diagnostic specimens that do not fit into a more specific diagnosis. This may involve atypical results in blood tests, tissue samples, or other bodily fluids.

When should I use R89 codes?

R89 codes should be used when a specimen shows abnormal findings that require further investigation but do not yet have a definitive diagnosis. It is essential to document the context of these findings to support the use of this code.

What documentation is required for R89?

Documentation should include the details of the abnormal findings, the context in which they were discovered, any follow-up actions taken, and the rationale for further diagnostic testing or monitoring.